Featured Research

from universities, journals, and other organizations

University Of Colorado Research Points To A Potential New Approach To AIDS Treatment

Date:
December 26, 2000
Source:
University Of Colorado Health Sciences Center
Summary:
Researchers at the University of Colorado Health Sciences Center have shown in laboratory studies that a molecule found in the human body can halt the growth of the AIDS virus.

Researchers at the University of Colorado Health Sciences Center have shown in laboratory studies that a molecule found in the human body can halt the growth of the AIDS virus. In a paper accepted for publication in the Federation of the American Societies of Experimental Biology (FASEB) Journal (January 1, 2001), the researchers describe various ways in which alpha-1 antitrypsin (AAT), a naturally-occurring protein in blood, prevents the AIDS virus from reproducing and from being spread to healthy cells. The AAT used in these investigations was purified from the blood of healthy volunteers who donated blood for research to the American Red Cross.

This novel path in AIDS research was led by Leland Shapiro, MD, assistant professor of medicine at CU-Health Sciences Center and principal investigator of the study. Several observations led the research team to search for a potent natural AIDS inhibitor in blood.

"In the laboratory, we confirmed the surprising observation that the AIDS virus did not grow in blood," Dr. Shapiro said. "This suggested that there was at least one substance in the blood that blocked the virus. We believe we have identified one of the substances as AAT, the most abundant inhibitor of serine proteases (natural enzymes that degrade proteins) in the blood."

The laboratory results were dramatic. Dr. Shapiro observed that although the AIDS virus did not proliferate when added to blood obtained from healthy volunteers, the virus replicated readily when added to blood from patients who had reduced AAT due to a genetic defect.

In other studies, the team found that in special cells designed to detect infection with the AIDS virus, AAT blocked the ability of the virus to infect previously healthy, uninfected cells. The research team next studied cells chronically infected with the AIDS virus. These cells can be induced by a variety of stimuli to produce high levels of AIDS virus. When these cells were stimulated in the presence of AAT, however, viral production was reduced by 90 percent to 100 percent compared to cells without AAT present.

This effect was observed regardless of the stimulus used to increase virus production in the cells. AAT also was able to stop replication of AIDS virus in natural, freshly infected blood mononuclear cells, a type of blood cell involved in fighting infections and healing wounds.

Dr. Shapiro and the research team propose that although AAT exists normally in the body, the AIDS virus appears to reproduce in areas where the amounts of AAT are low, such as in the lymph glands. By injecting infected patients with AAT it might be possible to increase AAT at the sites of viral replication. This might bolster the defense against the virus by preventing the production of AIDS virus from infected cells and blocking the spread of virus to healthy cells.

The research group also described experiments using a synthetic inhibitor of host serine proteases developed by Cortech to function as an AAT "mimic." This synthetic "mimic" possessed nearly identical effects as naturally-occurring AAT in inhibiting the AIDS virus. This suggests to the researchers that an oral agent (pill) eventually might be designed to treat AIDS.

"These findings are preliminary but promising," Dr. Shapiro said. "Inhibitors of serine proteases should be considered as candidates for treating the AIDS virus. If clinical results are as promising as what we have seen in the laboratory, methods of increasing AAT or use of an AAT "mimic" might be an effective form of AIDS therapy." Dr. Shapiro adds that the results of this research suggest that this approach to treatment may work regardless of viral mutations.

Clinical trials will be proposed to the AIDS Clinical Trials Group, which is based at the CU-Health Sciences Center. Additional laboratory studies and clinical studies in human subjects are required to determine the effectiveness of serine protease inhibitors like AAT or the AAT "mimic" in battling AIDS.

Christopher C. Lamb, CEO of the American Red Cross Plasma Services found the research results interesting. "The American Red Cross is pleased to have the opportunity to support such exciting and innovative research," he said.

The University of Colorado Health Sciences Center is one of four campuses in the University of Colorado system. Located in Denver, Colo., the campus includes schools of medicine, nursing, pharmacy, and dentistry, a graduate school and two hospitals.


Story Source:

The above story is based on materials provided by University Of Colorado Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Colorado Health Sciences Center. "University Of Colorado Research Points To A Potential New Approach To AIDS Treatment." ScienceDaily. ScienceDaily, 26 December 2000. <www.sciencedaily.com/releases/2000/12/001226081546.htm>.
University Of Colorado Health Sciences Center. (2000, December 26). University Of Colorado Research Points To A Potential New Approach To AIDS Treatment. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/12/001226081546.htm
University Of Colorado Health Sciences Center. "University Of Colorado Research Points To A Potential New Approach To AIDS Treatment." ScienceDaily. www.sciencedaily.com/releases/2000/12/001226081546.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins